ReviewSeminars in hematology2017
Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine.
Review in Seminars in hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Likes and Hashtags: Exploring the Potential Relationship Between Social Media Use and the Emotional Wellbeing of Oncology Professionals.Pediatric blood & cancer · 2025Article
- Development of a Medical Social Media Ethics Scale and Assessment of #IRad, #CardioTwitter, and #MedTwitter Posts: Mixed Methods Study.JMIR infodemiology · 2024Article
- A Scoping Review of Physician Advocacy on Twitter.Cureus · 2023Article
- Article
- Social Media and Professional Development for Oncology Professionals.JCO oncology practice · 2022Review
- Social Media and Oncology: The Time Is Now.JCO oncology practice · 2022Article
- #PauseBeforeYouPost: Ethical and Legal Issues Involving Medical Social Media.Seminars in interventional radiology · 2022Review
- Netiquette for social media engagement for oncology professionals.Future oncology (London, England) · 2022Review
- An evaluation of social media utilization by general surgery programs in the COVID-19 era.American journal of surgery · 2021Article
- Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Article
- Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges.Current hematologic malignancy reports · 2020Review
- Impact of Benign Hematology Didactic Lectures on In-service Exam in a Hematology-Oncology Fellowship Program: a Cross-sectional Longitudinal Study.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Article
- Popular Media and Cardiovascular Medicine: "with Great Power There Must Also Come Great Responsibility".Current atherosclerosis reports · 2019Review
- Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.Hepatology communications · 2019Article
- Article
- Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities.Current hematologic malignancy reports · 2018Review
- Online and Social Media Resources for Patients with MDS.Current hematologic malignancy reports · 2018Review
- Social media for pediatric research: what, who, why, and #?Pediatric research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Twitter use by physicians, including those in the hematology-oncology field, is increasing. This microblogging platform provides a means to communicate and collaborate on a global scale. For the oncology professional, an active Twitter presence provides opportunities for continuing medical education, patient engagement and education, personal branding, and reputation management. However, because Twitter is an open, public forum, potential risks such as patient privacy violations, personal information disclosures, professionalism lapses, and time management need to be considered and managed. The authors have summarized the benefits and risks of Twitter use by the hematology-oncology physician. In addition, strategies to maximize benefit and minimize risk are discussed, and resources for additional learning are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.